Miguel Lara
Founder/CEO● 10+ years as Digital Health startup CEO ● Deep relationships across the biopharma ecosystem ● 10+ years as Managing Director (healthcare) at global bank ● Y Combinator (YC_S15) alumni
Browser storage is unavailable. Keep this page open and export your collection before leaving.

* Category leading RWE platform generating differentiated data through combination of a provider community and patient-reported outcomes; delivering personalized and comparative evidence at the point of care
* Singular network architecture and data capturing capabilities help identify patients with unmet needs in real-time; unlocking opportunities to improve health outcomes and additional revenue for pharma
* Microhealth has achieved product-market fit in the hemophilia and rare blood disorders space
Today, we are the world's leader in digital hematology:
- Our US hemophilia network covers 33%+ of patients on prophylaxis and 50%+ of hemophilia treatment centers
- Average active-user retention is 52 months
- Trusted by leading pharmaceutical sponsors: Novo Nordisk, Sanofi, Roche and Pfizer
Previously MicroHealth
● 10+ years as Digital Health startup CEO ● Deep relationships across the biopharma ecosystem ● 10+ years as Managing Director (healthcare) at global bank ● Y Combinator (YC_S15) alumni
Expert indigital health, including: - Launching products for new therapeutic areas - Improving health outcomes - Clinical and HEOR studies - Domestic and global deployments - Predictive AI for medical and commercial goals
Founded 2015 · Source
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.